Journal Article Ppublish 13 citations
PubMed: 37982575 DOI: 10.1158/2159-8290.CD-22-1387
ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer.
Cancer Discov 14(2):274-289
Authors: Belinda Kingston, Alex Pearson, Maria Teresa Herrera-Abreu, Li-Xuan Sim, Rosalind J Cutts, Heena Shah, Laura Moretti, Lucy S Kilburn, Hannah Johnson, Iain R Macpherson, Alistair Ring, Judith M Bliss, Yingwei Hou, Weiyi Toy, John A Katzenellenbogen, Sarat Chandarlapaty, Nicholas C Turner
Affiliations
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.
- Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, United Kingdom.
- School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
- Breast Unit, The Royal Marsden Hospital, London, United Kingdom.
- Department of Chemistry and Cancer Center at Illinois, University of Illinois at Urbana-Champaign, Urbana, Illinois.
- Memorial Sloan Kettering Cancer Center, New York City, New York.
- Department of Medicine, Weill Cornell Medical College, New York City, New York.
MeSH
Fulvestrant, Breast Neoplasms, Neoplasms, Breast, Mutation
Cited by
- Understanding and overcoming CDK4/6 inhibitor resistance in HR+/HER2- metastatic breast cancer: clinical and molecular perspectives. Ther Adv Med Oncol, 2025
- The intersection of the HER2-low subtype with endocrine resistance: the role of interconnected signaling pathways. Front Oncol, 2024
- PARP-1 as a novel target in endocrine-resistant breast cancer. J Exp Clin Cancer Res, 2025
- Understanding mechanisms of Polygonatum sibiricum-derived exosome-like nanoparticles against breast cancer through an integrated metabolomics and network pharmacology analysis. Front Chem, 2025
- scPharm: Identifying Pharmacological Subpopulations of Single Cells for Precision Medicine in Cancers. Adv Sci (Weinh), 2025
- Circulating tumor DNA validity and potential uses in metastatic breast cancer. NPJ Breast Cancer, 2024
- Genomic Predictive Biomarkers in Breast Cancer: The Haves and Have Nots. Int J Mol Sci, 2025
- Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer. Breast, 2025
- Optimizing selective estrogen receptor degraders for anticancer drug development. Future Med Chem, 2025
- Exploring the multi-targeted mechanism of Saikosaponin A in prostate cancer treatment: a network pharmacology and molecular docking approach. Front Pharmacol, 2025